title: Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies.
authors.affiliation: First Department of Internal Medicine, Fukui Medical School, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ueda
authors.forename: S
authors.initials: S
authors.lastname: Matsuyama
authors.forename: T
authors.initials: T
authors.lastname: Yamauchi
authors.forename: S
authors.initials: S
authors.lastname: Kishi
authors.forename: T
authors.initials: T
authors.lastname: Fukushima
authors.forename: H
authors.initials: H
authors.lastname: Tsutani
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: N
authors.initials: N
authors.lastname: Gotoh
authors.forename: M
authors.initials: M
authors.lastname: Masada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001086:Arabinofuranosyluracil / Q000097:blood; D003561:Cytarabine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D001086:Arabinofuranosyluracil